Entera Bio (ENTX) Competitors $2.00 -0.06 (-2.91%) Closing price 04:00 PM EasternExtended Trading$1.99 -0.01 (-0.50%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENTX vs. FULC, ABEO, ALDX, ATXS, BNTC, ADCT, IMAB, ALT, CTMX, and CADLShould you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Aldeyra Therapeutics (ALDX), Astria Therapeutics (ATXS), Benitec Biopharma (BNTC), ADC Therapeutics (ADCT), I-Mab (IMAB), Altimmune (ALT), CytomX Therapeutics (CTMX), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry. Entera Bio vs. Its Competitors Fulcrum Therapeutics Abeona Therapeutics Aldeyra Therapeutics Astria Therapeutics Benitec Biopharma ADC Therapeutics I-Mab Altimmune CytomX Therapeutics Candel Therapeutics Entera Bio (NASDAQ:ENTX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Which has higher valuation & earnings, ENTX or FULC? Entera Bio has higher earnings, but lower revenue than Fulcrum Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntera Bio$180K507.33-$9.54M-$0.26-7.69Fulcrum Therapeutics$80M4.92-$9.73M-$1.22-5.96 Do analysts rate ENTX or FULC? Entera Bio currently has a consensus target price of $10.00, indicating a potential upside of 400.00%. Fulcrum Therapeutics has a consensus target price of $7.57, indicating a potential upside of 4.15%. Given Entera Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Entera Bio is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Fulcrum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63 Does the media prefer ENTX or FULC? In the previous week, Fulcrum Therapeutics had 2 more articles in the media than Entera Bio. MarketBeat recorded 4 mentions for Fulcrum Therapeutics and 2 mentions for Entera Bio. Fulcrum Therapeutics' average media sentiment score of 1.64 beat Entera Bio's score of 1.45 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is ENTX or FULC more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to Entera Bio's net margin of -4,525.11%. Fulcrum Therapeutics' return on equity of -31.05% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Entera Bio-4,525.11% -77.75% -68.13% Fulcrum Therapeutics N/A -31.05%-28.96% Do insiders & institutionals believe in ENTX or FULC? 14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 10.4% of Entera Bio shares are owned by company insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, ENTX or FULC? Entera Bio has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.82, meaning that its stock price is 182% more volatile than the S&P 500. SummaryFulcrum Therapeutics beats Entera Bio on 10 of the 16 factors compared between the two stocks. Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTX vs. The Competition Export to ExcelMetricEntera BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.32M$3.16B$5.77B$9.96BDividend YieldN/A2.27%6.70%4.53%P/E Ratio-7.6921.4375.8426.48Price / Sales507.33458.92541.63215.77Price / CashN/A44.1225.7029.11Price / Book8.709.7811.916.14Net Income-$9.54M-$53.22M$3.28B$265.92M7 Day Performance3.63%2.52%1.11%7.70%1 Month Performance9.89%11.45%8.17%11.82%1 Year Performance11.73%15.49%67.79%31.45% Entera Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTXEntera Bio1.7696 of 5 stars$2.00-2.9%$10.00+400.0%+15.1%$91.32M$180K-7.6920News CoverageShort Interest ↓Gap UpHigh Trading VolumeFULCFulcrum Therapeutics0.8835 of 5 stars$6.48-2.6%$7.57+16.8%-10.3%$350.51M$80M-5.31100News CoveragePositive NewsABEOAbeona Therapeutics4.4168 of 5 stars$6.83-0.7%$19.50+185.5%+24.1%$350.23M$3.50M9.7690ALDXAldeyra Therapeutics2.4178 of 5 stars$5.84-0.3%$9.50+62.7%-9.3%$349.79MN/A-6.8710ATXSAstria Therapeutics2.5983 of 5 stars$6.18-5.4%$29.00+369.3%-32.4%$348.77MN/A-3.0730BNTCBenitec Biopharma1.7654 of 5 stars$13.24+1.6%$26.00+96.4%+54.2%$347.56M$80K-8.7720News CoveragePositive NewsADCTADC Therapeutics2.9547 of 5 stars$3.08-5.4%$7.75+152.0%+30.7%$345.37M$70.84M-1.96310Short Interest ↓IMABI-Mab2.6738 of 5 stars$4.16-2.1%$7.00+68.3%+325.2%$339.71M$3.89M0.00380Positive NewsAnalyst ForecastALTAltimmune2.7152 of 5 stars$3.83+3.2%$17.40+354.3%-39.0%$338.02M$20K-3.2550CTMXCytomX Therapeutics4.2652 of 5 stars$2.04-0.5%$5.75+181.9%+90.0%$336.42M$138.10M3.64170Positive NewsCADLCandel Therapeutics2.3098 of 5 stars$5.79-0.5%$22.00+280.0%-18.6%$317.84M$120K-8.3960Analyst Downgrade Related Companies and Tools Related Companies Fulcrum Therapeutics Competitors Abeona Therapeutics Competitors Aldeyra Therapeutics Competitors Astria Therapeutics Competitors Benitec Biopharma Competitors ADC Therapeutics Competitors I-Mab Competitors Altimmune Competitors CytomX Therapeutics Competitors Candel Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTX) was last updated on 9/8/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredNot “should you own gold?” … But “Do you have enough?”Gold has already broken out to new all-time highs — and silver looks ready to surge even faster as it plays ca...Golden Portfolio | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTX Stock Alerts